In nonalcoholic steatohepatitis (NASH) models, the downregulation or absence of AGER1 decreased SLC7A11 expression, thereby inducing hepatocyte injury and exacerbating liver fibrosis [90]. Here, SLC7A11 is linked to metabolic dysfunction-associated steatohepatitis.